International survey on the management of IgA deficiency: The BEST Collaborative Study
Vox Sanguinis · 2026
DOI: 10.1111/vox.70311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2026. Verfasst von Renée Bazin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs and Innovation, Héma-Québec, Quebec City, Quebec, Canada. Hauptthemen laut MEDLINE: IgA Deficiency. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Objectives Selective immunoglobulin A (IgA) deficiency is the most common human immunodeficiency, affecting approximately 1 in 500–800 individuals of European ancestry. It is defined by a serum IgA level below 7 mg/dL, with normal immunoglobulin G (IgG) and immunoglobulin M (IgM) levels. Since 1968, severe allergic transfusion reactions have been reported in IgA‐deficient patients, often linked to anti‐IgA antibodies. This led to recommendations for using IgA‐deficient blood components in affected individuals. However, due to the rarity of such reactions, standardized and evidence‐based guidelines are lacking, while blood services face logistical challenges maintaining registries of IgA‐deficient donors and inventories of compatible products. Materials and Methods An international survey was conducted to assess current practices in managing IgA deficiency. The survey explored the frequency of transfusion reactions involving IgA/anti‐IgA, detection methods for IgA deficiency and anti‐IgA antibodies, reasons for requesting IgA‐deficient products, product availability and strategies to facilitate access to IgA‐deficient products.
Results
Participants from 14 countries/regions across four continents reported a wide variability in defining IgA deficiency, criteria for recommending IgA‐deficient products and anti‐IgA testing practices.
Conclusion
These findings highlight the need for international reference standards and harmonized recommendations to improve the management of IgA‐deficient patients. Establishing harmonized best practices and evidence‐based guidelines should enhance patient safety and support clinical decision making globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Affairs and Innovation, Héma-Québec, Quebec City, Quebec, Canada.
- Donation Policy and Studies, Canadian Blood Services, Ottawa, Ontario, Canada.
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Norwegian Center for Blood Preparedness, Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway.
- Faculty of Medicine, University of Bergen, Bergen, Norway.
- Transfusion Medicine, Héma-Québec, Montreal, Quebec, Canada.
ORCID-Profile: Mindy Goldman, Torunn Oveland Apelseth, Catherine Latour, Antoine Lewin, Nancy Robitaille
Zitieren
APA
Bazin, R., Goldman, M., Eichbaum, Q. G., Apelseth, T. O., Latour, C., Lewin, A., Robitaille, N., & Biomedical Excellence for Safer Transfusion Collaborative (2026). International survey on the management of IgA deficiency: The BEST Collaborative Study. Vox Sanguinis. https://doi.org/10.1111/vox.70311
Vancouver
Bazin R, Goldman M, Eichbaum QG, Apelseth TO, Latour C, Lewin A, et al. International survey on the management of IgA deficiency: The BEST Collaborative Study. Vox Sanguinis. 2026. doi:10.1111/vox.70311
BibTeX
@article{Bazin2026,
author = {Bazin, Renée and Goldman, Mindy and Eichbaum, Quentin G and Apelseth, Torunn Oveland and Latour, Catherine and Lewin, Antoine and Robitaille, Nancy and Biomedical Excellence for Safer Transfusion Collaborative, Biomedical Excellence for Safer Transfusion Collaborative},
title = {International survey on the management of IgA deficiency: The BEST Collaborative Study},
journal = {Vox Sanguinis},
year = {2026},
doi = {10.1111/vox.70311}
}
EUVIMED